Disease Model | AT1 Receptor Antagonist (dosage) | Suppression | Reference |
---|---|---|---|
DOCA-salt HT | Candesartan (1 mg/kg/day) | TGF-β1, FN, Co I, Co III, Co IV, laminin | Kim et al., 1994c |
SHRSP | Candesartan (0.1 mg/kg/day) | TGF-β1, FN, Co I, Co III, Co IV, laminin |
Kim et al., 1994b
|
Remnant kidney | Losartan (180 mg/L DW) | TGF-β1 | Junaid et al., 1997 |
Remnant kidney | Candesartan (1 mg/kg/day) | Phenotypic change (α-SMA, desmin) | Hamaguchi et al., 1996 |
Thy 1.1 GN | Losartan (500 mg/L DW) | TGF-β1, FN, PAI-1 | Peters et al., 1998 |
CsA nephropathy | Losartan (10 mg/kg/day) | TGF-β1, PAI-1, Co I, Co IV, biglycan | Shihab et al., 1997 |
HT, hypertensive rats; GN, glomerulonephritis; CsA, cyclosporin A; DW, drinking water; FN, fibronectin; Co, collagen; α-SMA, α-smooth muscle actin.